Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays
Owain Thomas, Emanuel Lybeck, Karin Strandberg, Nahreen Tynngård, Ulf Schött, Owain Thomas, Emanuel Lybeck, Karin Strandberg, Nahreen Tynngård, Ulf Schött
Abstract
Background: Low molecular weight heparins (LMWH's) are used to prevent and treat thrombosis. Tests for monitoring LMWH's include anti-factor Xa (anti-FXa), activated partial thromboplastin time (aPTT) and thrombin generation. Anti-FXa is the current gold standard despite LMWH's varying affinities for FXa and thrombin.
Aim: To examine the effects of two different LMWH's on the results of 4 different aPTT-tests, anti-FXa activity and thrombin generation and to assess the tests' concordance.
Method: Enoxaparin and tinzaparin were added ex-vivo in concentrations of 0.0, 0.5, 1.0 and 1.5 anti-FXa international units (IU)/mL, to blood from 10 volunteers. aPTT was measured using two whole blood methods (Free oscillation rheometry (FOR) and Hemochron Jr (HCJ)) and an optical plasma method using two different reagents (ActinFSL and PTT-Automat). Anti-FXa activity was quantified using a chromogenic assay. Thrombin generation (Endogenous Thrombin Potential, ETP) was measured on a Ceveron Alpha instrument using the TGA RB and more tissue-factor rich TGA RC reagents.
Results: Methods' mean aPTT at 1.0 IU/mL LMWH varied between 54s (SD 11) and 69s (SD 14) for enoxaparin and between 101s (SD 21) and 140s (SD 28) for tinzaparin. ActinFSL gave significantly shorter aPTT results. aPTT and anti-FXa generally correlated well. ETP as measured with the TGA RC reagent but not the TGA RB reagent showed an inverse exponential relationship to the concentration of LMWH. The HCJ-aPTT results had the weakest correlation to anti-FXa and thrombin generation (Rs0.62-0.87), whereas the other aPTT methods had similar correlation coefficients (Rs0.80-0.92).
Conclusions: aPTT displays a linear dose-response to LMWH. There is variation between aPTT assays. Tinzaparin increases aPTT and decreases thrombin generation more than enoxaparin at any given level of anti-FXa activity, casting doubt on anti-FXa's present gold standard status. Thrombin generation with tissue factor-rich activator is a promising method for monitoring LMWH's.
Conflict of interest statement
Competing Interests: One of the authors of this manuscript has the following competing interest: N. Tynngård is a part-time consultant to MediRox. The other authors have declared that no competing interests exist. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Figures
References
- Gouin-Thibault I, Pautas E, Siguret V (2005) Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Saf 28: 333–349.
- Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI (2002) In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 107: 241–244.
- Kitchen S, Jennings I, Woods TA, Preston FE (1996) Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 49: 10–14.
- Ip BK, Thomson AR, Moriarty HT (2001) A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin. Pathology 33: 347–352.
- Harris LF, Castro-Lopez V, Hammadi N, O’Donnell JS, Killard AJ (2010) Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins. Talanta 81: 1725–1730. 10.1016/j.talanta.2010.03.030
- Sibbing D, Spannagl M (2014) Direct oral anticoagulants and antiplatelet agents. Clinical relevance and options for laboratory testing. Hamostaseologie 34: 78–84. 10.5482/HAMO-13-11-0055
- Greaves M (2002) Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 87: 163–164.
- Benchekroun S, Eychenne B, Mericq O, Colombani A, Douste-Blazy P, et al. (1986) Heparin half-life and sensitivity in normal subjects and in patients affected by deep vein thrombosis. Eur J Clin Invest 16: 536–539.
- Al Dieri R, Alban S, Beguin S, Hemker HC (2006) Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 4: 83–89.
- Andrassy K, Eschenfelder V (1996) Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 81: S29–38.
- Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I (2007) Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 5: 955–962.
- Alban S, Welzel D, Hemker HC (2002) Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH. Semin Thromb Hemost 28: 369–378.
- al Dieri R, Alban S, Beguin S, Hemker HC (2004) Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2: 1395–1401.
- Gionis MN, Ioannou CV, Katsamouris AN, Katonis P, Balalis K, et al. (2013) The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement. Thromb Res 132: 685–691. 10.1016/j.thromres.2013.09.037
- Meysman M, Haentjens P (2005) Pulmonary embolism: current treatment options. Curr Treat Options Cardiovasc Med 7: 483–490.
- Sanfelippo MJ, Tillema VB (2009) Automated assay for fondaparinux (Arixtra) on the Dade Behring BCS XP. Am J Clin Pathol 132: 608–612. 10.1309/AJCPA8KNNLLCV4JI
- Takemoto CM, Streiff MB, Shermock KM, Kraus PS, Chen J, et al. (2013) Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance. Am J Clin Pathol 139: 450–456. 10.1309/AJCPS6OW6DYNOGNH
- Hainer JW, Barrett JS, Assaid CA, Fossler MJ, Cox DS, et al. (2002) Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 87: 817–823.
- Vermylen CG, Levin M, Lanham JG, Hardisty RM, Barratt TM (1987) Decreased sensitivity to heparin in vitro in steroid-responsive nephrotic syndrome. Kidney Int 31: 1396–1401.
- White RH, Ginsberg JS (2003) Low-molecular-weight heparins: are they all the same? Br J Haematol 121: 12–20.
- Kamal AH, Tefferi A, Pruthi RK (2007) How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 82: 864–873.
- Shi XB, Bai Y, Li J, Xiao J, Wang JQ, et al. (2013) Effects of low molecular weight heparin on clot rate and activated clotting time: an in vitro study. Chin Med J (Engl) 126: 3553–3556.
Source: PubMed